Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Pelthos Therapeutics ( (PTHS) ) is now available.
Pelthos Therapeutics announced its financial results for the third quarter of fiscal 2025, highlighting the successful commercial launch of ZELSUVMI, an FDA-approved at-home treatment for molluscum contagiosum, which generated $7.1 million in net revenues since its launch in July 2025. The company also completed the acquisition of XEPI, a topical treatment for impetigo, and secured $18 million in financing to support its operations. These developments position Pelthos to capitalize on large market opportunities and unmet needs in pediatric dermatology.
The most recent analyst rating on (PTHS) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
More about Pelthos Therapeutics
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products to address unmet patient needs. The company operates in the healthcare industry, with a market focus on dermatological treatments, particularly for conditions affecting children.
Average Trading Volume: 15,171
Technical Sentiment Signal: Strong Buy
Current Market Cap: $114.7M
See more data about PTHS stock on TipRanks’ Stock Analysis page.